Lates News

date
31/03/2026
According to AI Express of Every Economic News, Southwest Securities released a research report on March 31, giving a "buy" rating to Hengrui Medicine (600276.SH). The main reasons for the rating include: 1) Continuous achievements in innovative transformation and fundamental optimization of income structure; 2) Highlighted effectiveness of international BD, deep global value recognition; 3) Deep research and development pipeline, building a core moat for performance growth.
Latest
See all latestmore